Milestone

We are pleased to announce that our company has been notified by our Vietnamese partner, the Vinmec Research Institute of Stem Cell and Gene Technology (VRISG), that patient enrollment has been completed for the Phase I human clinical trial of our investigational new drug for diabetes (GXIPC1) in Vietnam.

On September 6, 2024, it was announced that the completion report for the Phase II clinical trial of the stem cell new drug, Si-Yi-You (GXNPC1), for the treatment of chronic stroke, has been acknowledged by the Ministry of Health and Welfare.

On September 9, 2024, an announcement was made that an application for a Phase III human clinical trial of the allogeneic stem cell new drug, Ruan-Shi-Li (GXCPC1), for the treatment of knee osteoarthritis, has been submitted to the Taiwan Food and Drug Administration (TFDA) under the Ministry of Health and Welfare.

On December 9, 2024, an announcement was made that the investigational new drug for diabetes, Yi-Dao-Su (GXIPC1), has received the draft of its Phase I clinical trial report in Vietnam.

The allogeneic stem cell new drug for the treatment of knee osteoarthritis, Ruan-Shi-Li (GXCPC1), was honored with the 2024 National Drug Technology Research and Development Award.

Patient enrollment for the Phase II human clinical trial of the stem cell new drug for chronic stroke, Si-Yi-You (GXNPC1), was completed on March 2.

On April 26, 2023, our company was approved for listing on the Emerging Stock Board (stock code: 6704).

On July 11, 2023, an announcement was made regarding the results of the evaluation endpoints from the Phase I/II human clinical trial of the allogeneic stem cell new drug for knee osteoarthritis, Ruan-Shi-Li (GXCPC1).

On October 2, 2023, an announcement was made regarding the results of the evaluation endpoints from the Phase II human clinical trial of the stem cell new drug for chronic stroke, Si-Yi-You (GXNPC1).

Received the 2022 Hsinchu County Local Industry Innovation and R&D Promotion Program (SBIR) - Outstanding Enterprise Award.

The stem cell new drug for the treatment of knee osteoarthritis, Ruan-Shi-Li (GXCPC1), was honored with the 2023 Hsinchu Science Park Outstanding Manufacturer Innovative Product Award.

The stem cell new drug for the treatment of chronic stroke, Si-Yi-You (GXNPC1), was honored with the 2023 National Innovation Award - Innovation Advancement Award.

Wanfang Hospital has been added as a clinical trial site for the stem cell new drug for the treatment of liver cirrhosis/fibrosis, Qing-Gan-Jing (GXHPC1).

Patient enrollment for the Phase I/II human clinical trial of the allogeneic stem cell new drug for the treatment of knee osteoarthritis, Ruan-Shi-Li (GXCPC1), was completed on April 28.

Our company has been notified by our Vietnamese partner, VRISG, that the first stage of patient enrollment has been completed for the Phase I human clinical trial of our investigational new drug for diabetes, Yi-Dao-Su (GXIPC1), in Vietnam.

The stem cell new drug for the treatment of chronic stroke, Si-Yi-You (GXNPC1), was honored with the 2022 Bronze Award in the Drug Category of the Ministry of Health and Welfare-Ministry of Economic Affairs Drug Technology Research and Development Award.

Received the 2022 Hsinchu Science Park R&D Achievement Award.

The stem cell new drug for the treatment of liver cirrhosis/fibrosis, Qing-Gan-Jing (GXHPC1), was honored with the 2022 National Innovation Award - Innovation Advancement Award.

The stem cell new drug for the treatment of chronic stroke, Si-Yi-You (GXNPC1), was honored with the 2022 National Innovation Award - Innovation Advancement Award.

The Phase II clinical trial plan for the stem cell new drug for the treatment of liver cirrhosis/fibrosis, Qing-Gan-Jing (GXHPC1), has been approved under the Ministry of Economic Affairs A+ Corporate Innovation and R&D Program (Fast-Track Review for Clinical Trial Plans).

Patient enrollment for the Phase I portion of the Phase I/II clinical trial of the stem cell new drug for knee osteoarthritis, Ruan-Shi-Li (GXCPC1), has been completed.

The allogeneic stem cell new drug for the treatment of diabetes, Yi-Dao-Su (GXIPC1), has been approved by the Ministry of Health of Vietnam to conduct a Phase I human clinical trial in Vietnam.

The allogeneic stem cell new drug for the treatment of knee osteoarthritis, Ruan-Shi-Li (GXCPC1), initiated a Phase II human clinical trial at Taipei Veterans General Hospital on October 13, and successfully enrolled the first subject.

The stem cell new drug for the treatment of chronic stroke, Si-Yi-You (GXNPC1), was honored with the 18th National Innovation Award - Corporate Innovation Award.

The stem cell new drug for the treatment of liver cirrhosis/fibrosis, Qing-Gan-Jing (GXHPC1), was honored with the 2021 National Innovation Award - Innovation Advancement Award.

The stem cell drug manufacturing facility has received the Green Building Label from the Taiwan Architecture and Building Center (TABC).

The stem cell new drug for chronic stroke, Si-Yi-You (GXNPC1), officially initiated a Phase II human clinical trial at Hualien Tzu Chi Medical Center and successfully enrolled the first patient on February 20 of the same year.

The stem cell new drug for liver cirrhosis/fibrosis, Qing-Gan-Jing (GXHPC1), officially initiated a Phase II human clinical trial at National Taiwan University Hospital and successfully enrolled its first patient on March 18 of the same year.

The stem cell new drug for the treatment of liver cirrhosis/fibrosis, Qing-Gan-Jing (GXHPC1), was honored with the 2020 Bronze Award in the Drug Category of the Ministry of Health and Welfare-Ministry of Economic Affairs Drug Technology Research and Development Award.

The construction of the stem cell pharmaceutical plant has been completed.

The new drug for knee osteoarthritis, Ruan-Shi-Li (GXCPC1), has been approved by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase I/II human clinical trial.

The stem cell new drug for the treatment of chronic stroke, Si-Yi-You (GXNPC1), was honored with the 2019 Taipei Biotech Awards - Innovative Technology Award, Excellence Prize.

The new drug for liver cirrhosis/fibrosis, Qing-Gan-Jing (GXHPC1), has been approved by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase II human clinical trial.

The new drug for chronic stroke, Si-Yi-You (GXNPC1), has been approved by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase II human clinical trial.

We have entered into a partnership with healthcare institutions under Vietnam's Vinmec Group to conduct a human clinical trial for diabetes stem cell therapy and jointly develop the new stem cell drug for diabetes, Yi-Dao-Su (GXIPC1).

The stem cell new drug for the treatment of liver cirrhosis/fibrosis, Qing-Gan-Jing (GXHPC1), was honored with the 2019 National Innovation Award - Innovation Advancement Award.

The stem cell new drug for the treatment of chronic stroke, Si-Yi-You (GXNPC1), was honored with the International Innovation Awards 2019.

The GTESTing® Testing Laboratory has passed its surveillance assessment for TAF ISO/IEC 17025:2017 accreditation, conducted by the Taiwan Accreditation Foundation (TAF).

In October, the company was certified as a Biotechnology and New Drug Company by the Ministry of Economic Affairs, in accordance with Article 3, Paragraph 2 of the Act for the Development of the Biotechnology and New Pharmaceutical Industry.

A topping-out ceremony for the new PIC/S GMP stem cell drug manufacturing facility was held on May 21 at the Hsinchu Biomedical Science Park.

The Clinical Cell Preparation Quality Inspection Service was certified with the SNQ National Quality Mark in the Medical Peripherals Category. The certification was granted by the National Biotechnology and Medical Care Industry Association.

The stem cell new drug for the treatment of liver cirrhosis/fibrosis, Qing-Gan-Jing (GXHPC1), was honored with the 15th National Innovation Award - Corporate Innovation Award.

The new drug for chronic stroke, Si-Yi-You (GXNPC1), has been approved by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase I human clinical trial.

The Medical-Grade Stem Cell Storage Service has been certified with the SNQ National Quality Mark in the Biotechnology Services Category.

Received the 23rd Ministry of Economic Affairs Small and Medium-sized Enterprise Innovation Research Award.

The new drug for liver cirrhosis/fibrosis, Qing-Gan-Jing (GXHPC1), has been approved by the Taiwan Food and Drug Administration (TFDA) to conduct a Phase I human clinical trial.

The stem cell preparation for the new drug for chronic stroke, Si-Yi-You (GXNPC1), has been certified under the Act for the Development of the Biotechnology and New Pharmaceutical Industry.

Received the Translational Excellence Award in the field of stem cell and regenerative medicine from the Ministry of Education's Pilot Program for Translational Medicine and Agricultural Talent Cultivation.

The GTESTing® Testing Laboratory (laboratory accreditation number: 2800) has been established and accredited by the Taiwan Accreditation Foundation (TAF) to the ISO/IEC 17025:2005 standard.

At the end of 2013, we completed a preclinical animal study for the stem cell new drug for the treatment of ischemic stroke, Si-Yi-You (GXNPC1), and obtained preliminary results.

The stem cell preparation for the new drug for the treatment of liver cirrhosis/fibrosis, Qing-Gan-Jing (GXHPC1), has been certified under the Act for the Development of the Biotechnology and New Pharmaceutical Industry.

A Stem Cell R&D Center and a GTP (Good Tissue Practice) Cell Processing Center were established at the Hsinchu Biomedical Science Park.

We developed the nutraceutical "Activation Protein" and successfully published our findings in an international journal.

The company has been approved by the National Science Council, Executive Yuan to move into the Hsinchu (Zhubei) Biomedical Science Park.

We have committed to the development of a new stem cell drug for the treatment of liver cirrhosis/fibrosis.